Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 52

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 52
---
 regimen of Tafenoquine; (ii) new products
that contain Tafenoquine; and (iii) Celgosivir.

Mission

Our mission is to address the unmet medical need associated with infectious
diseases through the development and commercialization of new small molecule therapeutics, focusing on synthetic drugs (made by chemists
in labs, excluding biologics) with good safety profiles based on prior clinical studies, in order to reduce cost, risk, and capitalize
on existing research. We are seeking to expand Arakoda’s use beyond malaria prevention and to demonstrate clinical benefit for other
disease indications. We are further testing the viability of another product (Celgosivir) to determine whether to advance it into further
clinical development, and may seek to develop and license other molecules in the future. Celgosivir is being considered for development
as an antiviral product for a number of diseases.

Market Opportunity

Malaria Prevention

In 2018, the FDA approved Arakoda
for malaria prevention in individuals 18 years and older. Arakoda entered the U.S. supply chain in the third quarter of 2019, just
prior to the COVID-19 pandemic. As the approved indication is for travel medicine, and international travel was substantially
impacted by the pandemic, we did not undertake any active marketing efforts for Arakoda. Following our recent financing the Company
hired a Chief Commercial Officer and commissioned IQVIA market data and a qualitative marketing demand study. That research,
recently completed, suggests that prescribing for malaria prevention therapies has returned to pre-pandemic levels, and that the
total U.S. market represents around 1.1 million prescriptions (one prescription per three weeks of travel). Based on consumer and
HCP demand research, the Company estimates that the accessible market for Arakoda represents about one third of this volume (about
330,000 prescriptions). Barriers to entry include low brand awareness in the prescriber community and the low cost of some of the
generic alternatives. In the second half of 2024 we will conduct a pilot commercialization study to confirm these barriers can be
overcome (see “Strategy”).

<div align='center'>1</div>

Treatment and Prevention of Tick-Borne Disease (Babesiosis) We are repositioning the Arakoda regimen of Tafenoquine for several potential new therapeutic indications that have substantial U.S. caseloads, as further described below: